Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise (CARDIBOX) (CARDIBOX)

13 marzo 2020 aggiornato da: University Hospital, Clermont-Ferrand

Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise

The high prevalence of childhood obesity is a major public health issue, worldwide. Childhood obesity is associated with a high risk of cardiovascular events in adulthood, but recent studies also point out the development of cardiovascular complications in childhood or adolescence justifying the need for early detection and appropriate therapeutic management to prevent the development of more severe abnormalities. This project proposes to evaluate the myocardial function in a fine and comprehensive way (longitudinal, circumferential and radial linear deformations, and rotation / torsion mechanics) from the deformation imaging (MRI and high-resolution echocardiography), in obese adolescents following a lifestyle intervention combining diet and physical activity.

Panoramica dello studio

Stato

Sconosciuto

Descrizione dettagliata

The investigators aim to improve knowledge of the association between epicardial adipose tissue, myocardial lipid content, and left ventricular regional myocardial function.

In this protocol, obese adolescents are recruited undergoing a 3-month lifestyle intervention residential program. Adolescents from the intervention group will be enrolled at the obesity center for the whole school year. The obesity center employs a multidisciplinary team to provide the best weight management care to adolescents during their stay. The weight loss program is an integral part of the obesity center program and fundamentally combines physical activity with a normocaloric diet monitored by a dietician. The physical activity program consists of two training sessions (aerobic and resistance training) per week. Moreover, adolescents will be engaged in two additional sessions per week, consisting in recreational activities such as ball and racquet games, trekking, snowshoeing or swimming.

There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.

Statistical analysis will be performed using Stata software (version 13; Stata-Corp, College Station, Tex., USA). All statistical tests will be two-sided and p inferior to 0.05 will be considered significant. Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of numbers, mean standard deviation or median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results. The main analysis will be performed with the Stata software (version 13, StataCorp, College Station). All statistical tests will be carried out at a risk of error of first species α set at 5%. Most of the analysis of the secondary evaluation criteria will be exploratory in nature and may lack power in terms of numbers. As discussed by Feise in 2002,104 the adjustment of the risk of error of 1st species will not be systematically proposed, but case by case in view of clinical considerations and not only statistical (e.g. Sidak correction for the analysis of correlation coefficients).

Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of standard deviation or mean median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results.

Intergroup comparisons will be systematically conducted without adjustment and by adjusting for factors whose distribution could be unbalanced between groups. Patients will be described and compared between groups at inclusion according to the following variables: compliance with eligibility criteria, epidemiological characteristics, clinical characteristics and characteristics of possible treatments. The baseline comparability of the two groups will be assessed on the main characteristics of the participants and potential factors associated with the primary outcome. A possible difference between the two groups on one of these characteristics will be determined according to clinical considerations and not solely statistical ones.

Tipo di studio

Interventistico

Iscrizione (Anticipato)

50

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Clermont-Ferrand, Francia, 63000
        • CHU de Clermont-Ferrand

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 12 anni a 16 anni (Bambino)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • age between 12 and 16 years old
  • mature (menarche)
  • suitable for physical activity
  • able to give an informative consent
  • affiliated at French insurance company
  • consent from the legal representatives
  • For obese adolescents: BMI greater than the 97th percentile of national curves.
  • For the control group: to be normal-weighted (no obesity if overweight, <85th percentile of national curves).

Exclusion Criteria:

  • Medical or surgical history judged by the investigator as incompatible with the study
  • Drugs that may interfere with the study results
  • Cardiovascular, hepatic, psychiatric, renal, or endocrinological diseases
  • Smoking
  • Alcohol consumption
  • Intense physical activity in competition

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Prevenzione
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Obese adolescents
BMI greater than the 97th percentile of national curves. Participants will follow a 3-month lifestyle intervention

Adolescents from the intervention group will be enrolled at the obesity center for the whole school year (i.e., 10 months). The physical activity program consists of two training sessions (aerobic and resistance training) per week.

There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.

Nessun intervento: Control group
to be normal-weighted (no obesity if overweight, <85th percentile of national curves).

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
cardiac ectopic fat deposits
Lasso di tempo: Month 3
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
Month 3
cardiac ectopic fat deposits
Lasso di tempo: Day 0
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
Day 0
cardiac ectopic fat deposits
Lasso di tempo: Day 0
Quantification of cardiac ectopic fat deposits (volume using MRI)
Day 0
cardiac ectopic fat deposits
Lasso di tempo: Month 3
Quantification of cardiac ectopic fat deposits (volume using MRI)
Month 3
cardiac ectopic fat deposits
Lasso di tempo: Month 3
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
Month 3
cardiac ectopic fat deposits
Lasso di tempo: Day 0
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
Day 0
left myocardial regional function
Lasso di tempo: Month 3
left myocardial regional function (echocardiography)
Month 3
left myocardial regional function
Lasso di tempo: Month 3
left myocardial regional function (MRI)
Month 3
left myocardial regional function
Lasso di tempo: Day 0
left myocardial regional function (echocardiography)
Day 0
left myocardial regional function
Lasso di tempo: Day 0
left myocardial regional function (MRI)
Day 0

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
macrovascularisation
Lasso di tempo: Day 0
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
Day 0
macrovascularisation
Lasso di tempo: Month 3
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
Month 3
microvascularisation
Lasso di tempo: Month 3
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
Month 3
microvascularisation
Lasso di tempo: Day 0
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
Day 0
microvascularisation
Lasso di tempo: Day 0
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
Day 0
microvascularisation
Lasso di tempo: Month 3
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
Month 3
microvascularisation
Lasso di tempo: Month 3
measure of microvascular perfusion using Iontophoresis procedure
Month 3
microvascularisation
Lasso di tempo: Day 0
measure of microvascular perfusion using Iontophoresis procedure
Day 0
microvascularisation
Lasso di tempo: Day 0
measure of microvascular perfusion using flowmotion
Day 0
microvascularisation
Lasso di tempo: Month 3
measure of microvascular perfusion using flowmotion
Month 3
heart rate variability
Lasso di tempo: Month 3
measure of heart rate variability using a holter
Month 3
heart rate variability
Lasso di tempo: Day 0
measure of heart rate variability using a holter
Day 0
skin conductance
Lasso di tempo: Day 0
measure of skin conductance using Wristband electrodes - Empatica E4
Day 0
skin conductance
Lasso di tempo: Month 3
measure of skin conductance using Wristband electrodes - Empatica E4
Month 3
Liver steatosis
Lasso di tempo: Month 3
measure of liver steatosis by MRI
Month 3
Liver steatosis
Lasso di tempo: Day 0
measure of liver steatosis by MRI
Day 0
Liver steatosis
Lasso di tempo: Day 0
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
Day 0
Liver steatosis
Lasso di tempo: Month 3
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
Month 3
Liver steatosis
Lasso di tempo: month 3
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
month 3
Liver steatosis
Lasso di tempo: Day 0
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
Day 0
Liver fibrosis
Lasso di tempo: Day 0
measure of liver fibrosis by fibroscanner (liver stiffness)
Day 0
Liver fibrosis
Lasso di tempo: Month 3
measure of liver fibrosis by fibroscanner (liver stiffness)
Month 3
Liver fibrosis
Lasso di tempo: Month 3
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
Month 3
Liver fibrosis
Lasso di tempo: Day 0
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
Day 0
blood pressure
Lasso di tempo: Day0
measure of blood pressure using sphygmomanometer
Day0
blood pressure
Lasso di tempo: month 3
measure of blood pressure using sphygmomanometer
month 3
Fitness
Lasso di tempo: Month 3
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
Month 3
Fitness
Lasso di tempo: Day 0
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
Day 0
muscle mass
Lasso di tempo: Month 3
measure of muscle mass using impedancemeter
Month 3
fat mass
Lasso di tempo: Month 3
measure of muscle mass using impedancemeter
Month 3
bone structure
Lasso di tempo: Month 3
measure of muscle mass using impedancemeter
Month 3
muscle mass
Lasso di tempo: Day 0
measure of muscle mass using impedancemeter
Day 0
fat mass
Lasso di tempo: Day 0
measure of muscle mass using impedancemeter
Day 0
bone structure
Lasso di tempo: Day 0
measure of muscle mass using impedancemeter
Day 0
muscle mass
Lasso di tempo: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
fat mass
Lasso di tempo: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
bone structure
Lasso di tempo: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
muscle mass
Lasso di tempo: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
fat mass
Lasso di tempo: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
bone structure
Lasso di tempo: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
muscle mass
Lasso di tempo: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
fat mass
Lasso di tempo: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
bone structure
Lasso di tempo: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
muscle mass
Lasso di tempo: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
fat mass
Lasso di tempo: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
bone structure
Lasso di tempo: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
muscle mass
Lasso di tempo: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
fat mass
Lasso di tempo: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
bone structure
Lasso di tempo: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
muscle mass
Lasso di tempo: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
fat mass
Lasso di tempo: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
bone structure
Lasso di tempo: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
depression
Lasso di tempo: Day 0
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
Day 0
depression
Lasso di tempo: Month 3
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
Month 3
anxiety
Lasso di tempo: Day 0
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always". It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
Day 0
anxiety
Lasso di tempo: Month 3
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always". It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
Month 3
General health
Lasso di tempo: Day 0
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
Day 0
General health
Lasso di tempo: Month 3
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
Month 3
Stress
Lasso di tempo: day 0
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
day 0
Stress
Lasso di tempo: Month 3
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Month 3
Fatigue
Lasso di tempo: Day 0
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Day 0
Fatigue
Lasso di tempo: Month 3
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Month 3
Sleep
Lasso di tempo: day 0
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
day 0
Sleep
Lasso di tempo: Month 3
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
Month 3
Burnout
Lasso di tempo: day 0
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
day 0
Burnout
Lasso di tempo: Month 3
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
Month 3
Mindfulness
Lasso di tempo: Day 0
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
Day 0
Mindfulness
Lasso di tempo: Month 3
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
Month 3
Coping
Lasso di tempo: Day 0
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
Day 0
Coping
Lasso di tempo: Month 3
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
Month 3
Emotions
Lasso di tempo: Day 0
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
Day 0
Emotions
Lasso di tempo: Month 3
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
Month 3
Perception of work
Lasso di tempo: Day 0
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree). It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
Day 0
Perception of work
Lasso di tempo: Month 3
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree). It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
Month 3
Self-efficacy
Lasso di tempo: Day 0
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
Day 0
Self-efficacy
Lasso di tempo: Month 3
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
Month 3
Alexithymia
Lasso di tempo: Day 0
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
Day 0
Alexithymia
Lasso di tempo: Month 3
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
Month 3
Illness perception
Lasso di tempo: Day 0
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
Day 0
Illness perception
Lasso di tempo: Month 3
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
Month 3
Metacognition
Lasso di tempo: Day 0
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
Day 0
Metacognition
Lasso di tempo: Month 3
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
Month 3
Time perception
Lasso di tempo: Day 0
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale. It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
Day 0
Time perception
Lasso di tempo: Month 3
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale. It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
Month 3
Physical activity
Lasso di tempo: Day 0
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
Day 0
Physical activity
Lasso di tempo: Month 3
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
Month 3
Life style
Lasso di tempo: Day 0
life style is assessed with a questionnaire on coffee consumption, food intake, etc
Day 0
Life style
Lasso di tempo: Month 3
life style is assessed with a questionnaire on coffee consumption, food intake, etc
Month 3
cholesterol
Lasso di tempo: Day 0
measure by blood analyses to evaluate alloplastic load
Day 0
triglycerides
Lasso di tempo: Day 0
measure by blood analyses to evaluate alloplastic load
Day 0
cholesterol
Lasso di tempo: Month 3
measure by blood analyses to evaluate alloplastic load
Month 3
triglycerides
Lasso di tempo: Month 3
measure by blood analyses to evaluate alloplastic load
Month 3
Cortisol
Lasso di tempo: Day 0
hormone measure by blood analyses to evaluate alloplastic load
Day 0
Cortisol
Lasso di tempo: Month 3
hormone measure by blood analyses to evaluate alloplastic load
Month 3
DHEAS
Lasso di tempo: day 0
hormone measure by blood analyses to evaluate alloplastic load
day 0
DHEAS
Lasso di tempo: Month 3
hormone measure by blood analyses to evaluate alloplastic load
Month 3
BDNF
Lasso di tempo: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
BDNF
Lasso di tempo: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
CRP
Lasso di tempo: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
pro-inflammatory cytokines
Lasso di tempo: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
TNF alpha
Lasso di tempo: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
CRP
Lasso di tempo: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
pro-inflammatory cytokines
Lasso di tempo: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
TNF alpha
Lasso di tempo: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
NPY
Lasso di tempo: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
NPY
Lasso di tempo: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
Leptin
Lasso di tempo: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Leptin
Lasso di tempo: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
Ghrelin
Lasso di tempo: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Ghrelin
Lasso di tempo: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
NPY
Lasso di tempo: day 0
measure by blood analyses to evaluate appetite regulation
day 0
NPY
Lasso di tempo: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
adiponectine
Lasso di tempo: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
adiponectine
Lasso di tempo: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
CCK
Lasso di tempo: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Month 3
Lasso di tempo: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Insulin
Lasso di tempo: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
Insulin
Lasso di tempo: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
HbA1c
Lasso di tempo: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
HbA1c
Lasso di tempo: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
glucose
Lasso di tempo: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
glucose
Lasso di tempo: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
Albumin
Lasso di tempo: Day 0
measure by blood analyses to evaluate protid metabolism
Day 0
Albumin
Lasso di tempo: Month 3
measure by blood analyses to evaluate protid metabolism
Month 3
transthyretin
Lasso di tempo: Day 0
measure by blood analyses to evaluate protid metabolism
Day 0
transthyretin
Lasso di tempo: Month 3
measure by blood analyses to evaluate protid metabolism
Month 3
Homeostasis
Lasso di tempo: Day 0
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
Day 0
Homeostasis
Lasso di tempo: Month 3
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
Month 3
Osteoresorption
Lasso di tempo: Day 0
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
Day 0
Osteoresorption
Lasso di tempo: Month 3
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
Month 3
Osteoformation
Lasso di tempo: Day 0
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
Day 0
Osteoformation
Lasso di tempo: Month 3
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
Month 3
VEGF
Lasso di tempo: Day 0
measure by blood analyses to evaluate cardiovascular function
Day 0
VEGF
Lasso di tempo: Month 3
measure by blood analyses to evaluate cardiovascular function
Month 3
PAI1
Lasso di tempo: Day 0
measure by blood analyses to evaluate cardiovascular function
Day 0
PAI1
Lasso di tempo: Month 3
measure by blood analyses to evaluate cardiovascular function
Month 3
weight
Lasso di tempo: Day 0
measure of weight in kilograms
Day 0
weight
Lasso di tempo: Month 3
measure of weight in kilograms
Month 3
waist circumference
Lasso di tempo: Day 0
measure of waist circumference in centimetres
Day 0
waist circumference
Lasso di tempo: Month 3
measure of waist circumference in centimetres
Month 3

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Anticipato)

1 settembre 2020

Completamento primario (Anticipato)

1 giugno 2021

Completamento dello studio (Anticipato)

1 giugno 2021

Date di iscrizione allo studio

Primo inviato

10 febbraio 2020

Primo inviato che soddisfa i criteri di controllo qualità

13 marzo 2020

Primo Inserito (Effettivo)

17 marzo 2020

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 marzo 2020

Ultimo aggiornamento inviato che soddisfa i criteri QC

13 marzo 2020

Ultimo verificato

1 febbraio 2020

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • RBHP 2019 DUTHEIL
  • 2019-A01804-53 (Altro identificatore: ANSM)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

Indeciso

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi